ASH 2018 | CAR-T and ibrutinib in combination: a promising treatment for CLL
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Lydia Scarfò, MD, of the Vita-Salute San Raffaele University, Milan, Italy, describes the new challenge of chronic lymphocytic leukemia (CLL) patients relapsing with novel agents. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Scarfò discusses how the use of CAR T-cell therapy is promising in terms of disease control and response, with improved efficacy when combined with ibrutinib, and therefore could be a mainstay in future therapy for CLL.
Get great new content delivered to your inboxSign up